文献速递临床试验与 GCP流行病学与生物统计

晚期癌症患者预立医疗照护计划:六国整群随机临床试验

Advance care planning in patients with advanced cancer: A 6-country, cluster-randomised clinical trial.
PubMed 文献 · PLoS Med · 2020-11-13

该研究在比利时、丹麦等六国23家医院开展整群随机试验,纳入1117例晚期肺癌或结直肠癌患者,评估ACTION Respecting Choices预立医疗照护计划(ACP)干预效果。结果显示干预组与对照组在生活质量、症状、应对、满意度及共享决策方面无显著差异,但干预组专科姑息治疗使用率和预立医疗指示入档率更高。

要点

  • ACP对话未改善晚期癌症患者生活质量及症状等结局。
  • 干预组专科姑息治疗使用率(37% vs 27%)和预立医疗指示入档率(10% vs 3%)更高。
  • 16%患者认为ACP对话带来困扰,需探索替代性支持方式。

核心结论

  • ACP对话与常规照护相比未显著改善患者生活质量。
  • 干预组专科姑息治疗使用和预立医疗指示入档更常见,需进一步研究。

研究设计与样本

  • 六国23家医院整群随机临床试验,2015-2018年纳入1117例晚期肺癌(III/IV期)或结直肠癌(IV期)患者。
  • 干预组442例接受ACTION Respecting Choices ACP干预,对照组675例接受常规照护。
  • 主要结局为生活质量和症状,809例(72%)完成12周问卷。

主要发现

  • 生活质量T评分变化干预组-1.8 vs 对照组-0.8,p=0.59,无显著差异。
  • 症状、应对、满意度及共享决策变化两组无差异。
  • 专科姑息治疗使用率干预组37% vs 对照组27%,p=0.002。
  • 预立医疗指示入档率干预组10% vs 对照组3%,p<0.001。
  • 每例患者平均ACP对话1.3次,保真度86%,16%患者感到困扰。

临床怎么用

  • ACP干预可提高专科姑息治疗使用和预立医疗指示入档,但未改善生活质量。
  • 需关注部分患者对ACP对话的困扰,考虑替代性支持方式。

局限性

  • 干预医院招募率低于对照医院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advance care planning (ACP) supports individuals to define, discuss, and record goals and preferences for future medical treatment and care. Despite being internationally recommended, randomised clinical trials of ACP in patients with advanced cancer are scarce. METHODS AND FINDINGS: To test the implementation of ACP in patients with advanced cancer, we conducted a cluster-randomised trial in 23 hospitals across Belgium, Denmark, Italy, Netherlands, Slovenia, and United Kingdom in 2015-2018. Patients with advanced lung (stage III/IV) or colorectal (stage IV) cancer, WHO performance status 0-3, and at least 3 months life expectancy were eligible. The ACTION Respecting Choices ACP intervention as offered to patients in the intervention arm included scripted ACP conversations between patients, family members, and certified facilitators; standardised leaflets; and standardised advance directives. Control patients received care as usual. Main outcome measures were quality of life (operationalised as European Organisation for Research and Treatment of Cancer [EORTC] emotional functioning) and symptoms. Secondary outcomes were coping, patient satisfaction, shared decision-making, patient involvement in decision-making, inclusion of advance directives (ADs) in hospital files, and use of hospital care. In all, 1,117 patients were included (442 intervention; 675 control), and 809 (72%) completed the 12-week questionnaire. Patients' age ranged from 18 to 91 years, with a mean of 66; 39% were female. The mean number of ACP conversations per patient was 1.3. Fidelity was 86%. Sixteen percent of patients found ACP conversations distressing. Mean change in patients' quality of life did not differ between intervention and control groups (T-score -1.8 versus -0.8, p = 0.59), nor did changes in symptoms, coping, patient satisfaction, and shared decision-making. Specialist palliative care (37% versus 27%, p = 0.002) and AD inclusion in hospital files (10% versus 3%, p < 0.001) were more likely in the intervention group. A key limitation of the study is that recruitment rates were lower in intervention than in control hospitals. CONCLUSIONS: Our results show that quality of life effects were not different between patients who had ACP conversations and those who received usual care. The increased use of specialist palliative care and AD inclusion in hospital files of intervention patients is meaningful and requires further study. Our findings suggest that alternative approaches to support patient-centred end-of-life care in this population are needed. TRIAL REGISTRATION: ISRCTN registry ISRCTN63110516.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Korfage IJ, Carreras G, Arnfeldt Christensen CM, et al. Advance care planning in patients with advanced cancer: A 6-country, cluster-randomised clinical trial. PLoS Med. 2020. PMID: 33186365. doi:10.1371/journal.pmed.1003422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。